Abstract 2344
Background
Hormone receptor-positive, HER2-negative, pT1ab N0 breast cancers (BC) are generally estimated as having a low risk of recurrence after locoregional treatment and adjuvant treatment decisions could be challenging. We examined the impact of endocrine therapy (ET) +/- chemotherapy on outcomes in this population.
Methods
A total of 4,788 patients with pT1ab N0 HR+ HER2- BC were identified from a large cohort of 22,475 consecutive patients who underwent primary surgery at 15 French centres between 2000 and 2014. Endpoints were disease-free survival (DFS) and overall survival (OS). Analyses of causal effect using propensity scores were realized using a logistic regression including age, tumour size, histology, grade, and lymphovascular invasion (LVI).
Results
Of 4,779 patients with pT1ab HR+ HER2- BC, 846 patients did not receive any adjuvant treatment and 3,933 received ET, among which 251 received chemotherapy. Age ≥ 70y, ductal histology, high grade and tumour size > 5mm were independently associated with ET prescription. Age ≤ 40y, LVI and high grade, were independently associated with chemotherapy prescription. At a median follow-up of 47.7 months, ET was independently associated with a significant DFS benefit in multivariate analysis (HR: 0.60 [0.41-0.89]; p = 0.011) with 5-year estimate DFS of 94% (CI95 [92-96%]) without ET vs. 96% (CI95 [95-97%]) with ET, while addition of adjuvant chemotherapy was not (HR: 0.90 [0.39-2.09]; p = 0.813). These results were supported by the analyses of causal effect using propensity scores (HR: 0.48 [0.28-0.83]; p = 0.009 for ET, and HR: 1.54 [0.11-21.8]; p = 0.78 for chemotherapy). OS was not significantly impacted by systemic treatments despite a trend for ET in multivariate (HR: 0.60 [0.36-1.00]; p = 0.051) and in propensity score analyses (HR: 0.52 [0.24-1.11]; p = 0.092).
Conclusions
Adjuvant endocrine therapy is associated with a survival benefit in pT1ab N0 HR+ HER2- BC even with a relatively short follow up. Consistent with current consensus guidelines that do not recommend adjuvant chemotherapy in these tumours, we did not find any benefit of adding chemotherapy to ET. These data provide additional clues to the issue of adjuvant systemic treatments in these tumours.
Clinical trial identification
Legal entity responsible for the study
Gilles Houvenaeghel.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4942 - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Presenter: Tony Loughman
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract